CTIS.eu › Cities › France › Marseille
Marseille
France
1,485 total trials
664 recruiting
Filter these 1,485 trials by phase, condition, sponsor and more.
Open in Search →
2022-500609-42-00
4
2023-02-24
Anemia Due to Lower-Risk Myelodysplastic Syndromes
2023-509672-42-00
5
2023-02-02
GRIN-related neurodevelopmental disorder
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
2022-500391-62-00
9
2023-01-19
Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
2023-503795-24-00
7
2022-09-16
Avanced Non-Small Cell Lung Cancer
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
2023-507379-23-00
10
2022-08-18
Generalized Myasthenia Gravis
2024-513185-19-00
9
2022-07-13
Extensive stage small cell lung cancer (ES-SCLC)
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
2023-504084-17-00
9
2021-07-12
ALK fusion-positive extracranial solid or primary CNS tumors who have
2023-506581-31-00
1
2021-06-15
Acute Leukemia
2022-501677-39-00
5
2021-05-25
Adolescent Renal Allografts
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
2022-500966-82-00
5
2020-03-11
Resectable locally advanced squamous cell carcinoma (SCC) of the esoph
2022-502784-37-00
4
2019-09-03
Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 ye
2024-511855-16-00
5
2019-07-25
Onco-hematology
2024-516807-17-00
4
2019-01-02
Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
2023-508587-29-00
4
2018-04-03
Treatment of high-risk neuroblastoma patients with primary refractory
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
2023-505805-18-00
5
2026-05-27
Hemophilia B
2025-521702-18-00
1
2026-05-21
Locally advanced unresectable or metastatic colorectal cancer (CRC)
2024-517337-41-00
5
2026-05-12
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
Showing 265–288 of 1,485 trials